918 related articles for article (PubMed ID: 20206786)
1. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
2. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
[TBL] [Abstract][Full Text] [Related]
6. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
Kramer M; Simpson G; Maciulis V; Kushner S; Vijapurkar U; Lim P; Eerdekens M
J Clin Psychopharmacol; 2007 Feb; 27(1):6-14. PubMed ID: 17224706
[TBL] [Abstract][Full Text] [Related]
7. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
Fowler JA; Bettinger TL; Argo TR
Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
[TBL] [Abstract][Full Text] [Related]
8. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
Canuso CM; Youssef EA; Bossie CA; Turkoz I; Schreiner A; Simpson GM
Int Clin Psychopharmacol; 2008 Jul; 23(4):209-15. PubMed ID: 18545059
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.
Luthringer R; Staner L; Noel N; Muzet M; Gassmann-Mayer C; Talluri K; Cleton A; Eerdekens M; Battisti WP; Palumbo JM
Int Clin Psychopharmacol; 2007 Sep; 22(5):299-308. PubMed ID: 17690599
[TBL] [Abstract][Full Text] [Related]
10. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.
Janicak PG; Wu JH; Mao L
Curr Med Res Opin; 2008 Jun; 24(6):1807-15. PubMed ID: 18559166
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder.
Vieta E; Nuamah IF; Lim P; Yuen EC; Palumbo JM; Hough DW; Berwaerts J
Bipolar Disord; 2010 May; 12(3):230-43. PubMed ID: 20565430
[TBL] [Abstract][Full Text] [Related]
13. Paliperidone extended-release for the treatment of schizophrenia.
Marino J; Caballero J
Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223
[TBL] [Abstract][Full Text] [Related]
14. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
Kim SW; Yoon JS; Kim YS; Ahn YM; Kim CE; Go HJ; Chee IS; Jung SW; Chung YC; Kim YD; Joe S; Lee J; Kwon YJ; Yoon BH; Jae YM
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):228-35. PubMed ID: 22516251
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.
Singh J; Robb A; Vijapurkar U; Nuamah I; Hough D
Biol Psychiatry; 2011 Dec; 70(12):1179-87. PubMed ID: 21831359
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M
Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492
[TBL] [Abstract][Full Text] [Related]
17. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.
Kane J; Canas F; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
Schizophr Res; 2007 Feb; 90(1-3):147-61. PubMed ID: 17092691
[TBL] [Abstract][Full Text] [Related]
18. Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study.
Schmauss M; Jukić V; Siracusano A; Bidzan L; Badescu GM; Maciulis V; Lahaye M; Hoeben D; Tessier C; Schreiner A
Curr Med Res Opin; 2012 Aug; 28(8):1395-404. PubMed ID: 22746355
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
20. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]